Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
BENCH-PRESS : Original Article
BEYOND CLINICAL ONCOLOGY : Original Article
Brainteaser
BREAST CANCER : Original Article
BREAST CANCERS Original Article
Brief Commentary MEDic LAWgic Section
Brief Report, Infections
Brief Report, Public Health
CANCER EPIDEMIOLOGY: Original Article
CANCER SURGERY : Original Article
Cardio-Oncology
Case Report
Case Series, Haematological
CLINICAL TRIAL : Original Article
COLORECTAL CANCER : Original Article
COMMENTARY
Consensus
Consensus Recommendations, Head Neck
Controversy
Corrigendum
Diagnostic Dilemma
Drug Review
DRUG REVIEW : Review Article
Editorial
Editorial Board
Editorial Commentary
Editorial: Memoir
Erratum
ESOPHAGEAL CANCER : Original Article
FEMALE REPRODUCTIVE TRACT TUMORS : Original Article
GCT Review Article
GENITOURINARY : Original Article
GI CANCER Original Article
HEAD AND NECK CANCER : Original Article
HEAD AND NECK CANCER : Review Article
HEAD AND NECK CANCERS : Original Article
HISTOPATHOLOGY IN ONCOLOGY : Original Article
In Response
Letter to Editor
Letter to Editor, Artificial Intelligence
Letter to Editor, Bone Soft Tissue
Letter to Editor, Breast
Letter to Editor: Oral Carcinoma
Letter to the Editor
Letters to Editor
Letters to the Editor
LEUKEMIA : Original Article
LEUKEMIAS : Original Article
LUNG CANCER: Original Article
METRONOMIC THERAPY IN AML : Original Article
METRONOMIC THERAPY IN HEAD AND NECK CANCERS : Original Article
METRONOMIC THERAPY IN LUNG CANCER : Original Article
METRONOMIC THERAPY IN OVARIAN CANCER : Original Article
Mini Commentary
Mini Symposium - FNAC VERSUS CORE BIOPSY: Editorial
Mini Symposium - FNAC VERSUS CORE BIOPSY: Original Article
Mini Symposium - RT DOSIMETRY AND FRACTIONATION: Editorial
Mini Symposium - RT DOSIMETRY AND FRACTIONATION: Original Article
Mini Symposium on Changing Landscape: Brief Article
Mini Symposium on Changing Landscape: Editorial
Mini Symposium on Changing Landscape: Original Article
Mini Symposium on CML
Mini Symposium on Supportive Care: Original Article
MINI SYMPOSIUM: HEAD AND NECK CANCER : Editorial
MINI SYMPOSIUM: HEAD AND NECK CANCER : Original Article
MINI SYMPOSIUM: HEAD AND NECK CANCER : Review Article
MINI SYMPOSIUM: HEAD AND NECK ONCOLOGY: Original Article
MINI SYMPOSIUM: MOLECULAR ONCOLOGY: Original Article
MINI SYMPOSIUM: PEDIATRIC ONCOLOGY: Original Article
MISCELLANEOUS : Original Article
MOLECULAR ONCOLOGY : Original Article
MULTIPLE CANCERS Original Article
MYELODYSPLASTIC SYNDROME : Review Article
MYELOID LEUKEMIA : Original Article
NEURO ONCOLOGY : Review Article
NEURO-ONCOLOGY : Original Article
None
Notice of Retraction
OESOPHAGEAL CANCER : Original Article
Oncology Reflections
Original Article
Original Article : Bone & Soft Tissue Tumors
ORIGINAL ARTICLE : Bone and Soft Tissue Sarcomas
ORIGINAL ARTICLE : Breast Cancer
Original Article : Breast Cancers
Original Article : Gastro-intestinal & Hepatobiliary Cancers
Original Article : Genitourinary & Gynecological Cancers
ORIGINAL ARTICLE : GI Cancer
ORIGINAL ARTICLE : GI Oncology
ORIGINAL ARTICLE : Gynaecologic Oncology
Original Article : Head and Neck Cancers
ORIGINAL ARTICLE : Hematolymphoid
Original Article : Leukemia & Lymphoma
ORIGINAL ARTICLE : Leukemia and Lymphoma
ORIGINAL ARTICLE : Melanoma and Skin Cancer
Original Article : Pediatric and Adolescent Cancers
ORIGINAL ARTICLE : SAARC Selection
ORIGINAL ARTICLE : Supportive Care and Others
Original Article, Adolescent and Young Adult
Original Article, Artificial Intelligence
Original Article, Bone Soft Tissue
Original Article, Breast
Original Article, Gastro Intestinal
Original Article, Gastrointestinal
Original Article, Gynaecological
Original Article, Gynaecology
Original Article, Head Neck
Original Article, Infections
Original Article, Lung
Original Article, Molecular
Original Article, Neurological
Original Article, Public Health
Original Article: Bladder Cancer
Original Article: Bone and Soft Tissue Cancers
Original Article: Bone and Soft Tissue Tumor
ORIGINAL ARTICLE: Bone and Soft Tissue Tumors
Original Article: Brain Tumor
ORIGINAL ARTICLE: Brain Tumors
Original Article: Cancer Epidemiology and Screening
Original Article: Cancer Epidemiology, Screening and diagnosis
ORIGINAL ARTICLE: Diagnostics in Oncology
ORIGINAL ARTICLE: Epidemiology of Cancer and Cancer Screening
ORIGINAL ARTICLE: Gastro-intestinal & Hepatobiliary Cancer
Original Article: Gastrointestinal Cancer
Original Article: Genito Urinary Cancer
ORIGINAL ARTICLE: Genitourinary & Gynaecological Cancer
Original Article: Genitourinary Cancer
ORIGINAL ARTICLE: Genitourinary Cancers
Original Article: Geriatric Oncology
ORIGINAL ARTICLE: GI Cancers
Original Article: GI Cancers and Hepatobilliary Malignancies
ORIGINAL ARTICLE: Gynaecologic Cancers
ORIGINAL ARTICLE: Gynaecological Cancer
ORIGINAL ARTICLE: Gynaecological Cancers
Original Article: Gynecological Cancer
ORIGINAL ARTICLE: Head and Neck Cancer
ORIGINAL ARTICLE: Hematolymphoid Malignancies
Original Article: Hematolymphoid Malignancy
Original Article: Hepatobiliary Cancer
ORIGINAL ARTICLE: Immuno - Oncology
Original Article: Leukemia -Lymphoma and Myeloma
ORIGINAL ARTICLE: Leukemia, Lymphoma & Plasma Cell Disorder
Original Article: Lung Cancer
ORIGINAL ARTICLE: Lung Cancers
ORIGINAL ARTICLE: Neuroendocrine Tumors
Original Article: Paediatric Cancer
ORIGINAL ARTICLE: Palliative Care
ORIGINAL ARTICLE: Pediatric Oncology
ORIGINAL ARTICLE: Sarcomas
ORIGINAL ARTICLE: Sarcomas and Skin Cancer
Original Article: Skin Cancer
Original Article: Supportive and Palliative Care
Original Article: Supportive and Palliative Care in Cancer
ORIGINAL ARTICLE: Supportive Care
Original Research Article
PEDIATRIC ONCOLOGY : Original Article
PEDIATRIC SECTION: Editorial
PEDIATRIC SECTION: Original Article
Pictorial CME, Haematological
Poetry in Oncology
Position Paper
QUEST FOR AN ANTIDOTE TO RADIATION TOXICITY : Editorial
QUEST FOR AN ANTIDOTE TO RADIATION TOXICITY : Original Article
RCC Practical Consensus Recommendations
Regional Article
Review Article
Review Article, Breast
Review Article, Gastro Intestinal
Review Article, Haematological
Review Article, International
Review Article, Nervous System
Review Consensus, Geriatric Oncology
SARCOMA : Original Article
SARCOMA Review Article
SOFT TISSUE SARCOMA : Original Article
South Asia update
SOUTH ASIAN UPDATE : An update
SOUTH ASIAN UPDATE : Original Article
TABACCO, THE MENACE : Original Article
THE CUTTING EDGE OF RADIOTHERAPEUTICS : Editorial
THE CUTTING EDGE OF RADIOTHERAPEUTICS : Original Article
THE GREAT DEBATE: Against HPV vaccine in cervical cancer
THE GREAT DEBATE: AGAINST IMATINIB AS THE FIRST LINE TKI CHOICE FOR CML
THE GREAT DEBATE: Editorial-HPV vaccine in cervical cancer
THE GREAT DEBATE: For HPV vaccine in cervical cancer
THE GREAT DEBATE: FOR IMATINIB AS THE FIRST LINE TKI CHOICE FOR CML
THE GREY-HAIRED CANCER PATIENT: Editorial
THE GREY-HAIRED CANCER PATIENT: Original Article
THE SKILLFUL SCALPEL: Editorial
THE SKILLFUL SCALPEL: Original Article
THE WAR ON MICROBES: Editorial
THE WAR ON MICROBES: Original Article
THROUGH THE MICROSCOPE : Original Article
THROUGH THE MICROSCOPE: Editorial
TREATMENT TOXICITY : Original Article
TRENDS IN HORMONAL THERAPY IN PROSTATE CANCER: Review Article
URO-ONCOLOGY : Original Article
View Point
Viewpoint
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
BENCH-PRESS : Original Article
BEYOND CLINICAL ONCOLOGY : Original Article
Brainteaser
BREAST CANCER : Original Article
BREAST CANCERS Original Article
Brief Commentary MEDic LAWgic Section
Brief Report, Infections
Brief Report, Public Health
CANCER EPIDEMIOLOGY: Original Article
CANCER SURGERY : Original Article
Cardio-Oncology
Case Report
Case Series, Haematological
CLINICAL TRIAL : Original Article
COLORECTAL CANCER : Original Article
COMMENTARY
Consensus
Consensus Recommendations, Head Neck
Controversy
Corrigendum
Diagnostic Dilemma
Drug Review
DRUG REVIEW : Review Article
Editorial
Editorial Board
Editorial Commentary
Editorial: Memoir
Erratum
ESOPHAGEAL CANCER : Original Article
FEMALE REPRODUCTIVE TRACT TUMORS : Original Article
GCT Review Article
GENITOURINARY : Original Article
GI CANCER Original Article
HEAD AND NECK CANCER : Original Article
HEAD AND NECK CANCER : Review Article
HEAD AND NECK CANCERS : Original Article
HISTOPATHOLOGY IN ONCOLOGY : Original Article
In Response
Letter to Editor
Letter to Editor, Artificial Intelligence
Letter to Editor, Bone Soft Tissue
Letter to Editor, Breast
Letter to Editor: Oral Carcinoma
Letter to the Editor
Letters to Editor
Letters to the Editor
LEUKEMIA : Original Article
LEUKEMIAS : Original Article
LUNG CANCER: Original Article
METRONOMIC THERAPY IN AML : Original Article
METRONOMIC THERAPY IN HEAD AND NECK CANCERS : Original Article
METRONOMIC THERAPY IN LUNG CANCER : Original Article
METRONOMIC THERAPY IN OVARIAN CANCER : Original Article
Mini Commentary
Mini Symposium - FNAC VERSUS CORE BIOPSY: Editorial
Mini Symposium - FNAC VERSUS CORE BIOPSY: Original Article
Mini Symposium - RT DOSIMETRY AND FRACTIONATION: Editorial
Mini Symposium - RT DOSIMETRY AND FRACTIONATION: Original Article
Mini Symposium on Changing Landscape: Brief Article
Mini Symposium on Changing Landscape: Editorial
Mini Symposium on Changing Landscape: Original Article
Mini Symposium on CML
Mini Symposium on Supportive Care: Original Article
MINI SYMPOSIUM: HEAD AND NECK CANCER : Editorial
MINI SYMPOSIUM: HEAD AND NECK CANCER : Original Article
MINI SYMPOSIUM: HEAD AND NECK CANCER : Review Article
MINI SYMPOSIUM: HEAD AND NECK ONCOLOGY: Original Article
MINI SYMPOSIUM: MOLECULAR ONCOLOGY: Original Article
MINI SYMPOSIUM: PEDIATRIC ONCOLOGY: Original Article
MISCELLANEOUS : Original Article
MOLECULAR ONCOLOGY : Original Article
MULTIPLE CANCERS Original Article
MYELODYSPLASTIC SYNDROME : Review Article
MYELOID LEUKEMIA : Original Article
NEURO ONCOLOGY : Review Article
NEURO-ONCOLOGY : Original Article
None
Notice of Retraction
OESOPHAGEAL CANCER : Original Article
Oncology Reflections
Original Article
Original Article : Bone & Soft Tissue Tumors
ORIGINAL ARTICLE : Bone and Soft Tissue Sarcomas
ORIGINAL ARTICLE : Breast Cancer
Original Article : Breast Cancers
Original Article : Gastro-intestinal & Hepatobiliary Cancers
Original Article : Genitourinary & Gynecological Cancers
ORIGINAL ARTICLE : GI Cancer
ORIGINAL ARTICLE : GI Oncology
ORIGINAL ARTICLE : Gynaecologic Oncology
Original Article : Head and Neck Cancers
ORIGINAL ARTICLE : Hematolymphoid
Original Article : Leukemia & Lymphoma
ORIGINAL ARTICLE : Leukemia and Lymphoma
ORIGINAL ARTICLE : Melanoma and Skin Cancer
Original Article : Pediatric and Adolescent Cancers
ORIGINAL ARTICLE : SAARC Selection
ORIGINAL ARTICLE : Supportive Care and Others
Original Article, Adolescent and Young Adult
Original Article, Artificial Intelligence
Original Article, Bone Soft Tissue
Original Article, Breast
Original Article, Gastro Intestinal
Original Article, Gastrointestinal
Original Article, Gynaecological
Original Article, Gynaecology
Original Article, Head Neck
Original Article, Infections
Original Article, Lung
Original Article, Molecular
Original Article, Neurological
Original Article, Public Health
Original Article: Bladder Cancer
Original Article: Bone and Soft Tissue Cancers
Original Article: Bone and Soft Tissue Tumor
ORIGINAL ARTICLE: Bone and Soft Tissue Tumors
Original Article: Brain Tumor
ORIGINAL ARTICLE: Brain Tumors
Original Article: Cancer Epidemiology and Screening
Original Article: Cancer Epidemiology, Screening and diagnosis
ORIGINAL ARTICLE: Diagnostics in Oncology
ORIGINAL ARTICLE: Epidemiology of Cancer and Cancer Screening
ORIGINAL ARTICLE: Gastro-intestinal & Hepatobiliary Cancer
Original Article: Gastrointestinal Cancer
Original Article: Genito Urinary Cancer
ORIGINAL ARTICLE: Genitourinary & Gynaecological Cancer
Original Article: Genitourinary Cancer
ORIGINAL ARTICLE: Genitourinary Cancers
Original Article: Geriatric Oncology
ORIGINAL ARTICLE: GI Cancers
Original Article: GI Cancers and Hepatobilliary Malignancies
ORIGINAL ARTICLE: Gynaecologic Cancers
ORIGINAL ARTICLE: Gynaecological Cancer
ORIGINAL ARTICLE: Gynaecological Cancers
Original Article: Gynecological Cancer
ORIGINAL ARTICLE: Head and Neck Cancer
ORIGINAL ARTICLE: Hematolymphoid Malignancies
Original Article: Hematolymphoid Malignancy
Original Article: Hepatobiliary Cancer
ORIGINAL ARTICLE: Immuno - Oncology
Original Article: Leukemia -Lymphoma and Myeloma
ORIGINAL ARTICLE: Leukemia, Lymphoma & Plasma Cell Disorder
Original Article: Lung Cancer
ORIGINAL ARTICLE: Lung Cancers
ORIGINAL ARTICLE: Neuroendocrine Tumors
Original Article: Paediatric Cancer
ORIGINAL ARTICLE: Palliative Care
ORIGINAL ARTICLE: Pediatric Oncology
ORIGINAL ARTICLE: Sarcomas
ORIGINAL ARTICLE: Sarcomas and Skin Cancer
Original Article: Skin Cancer
Original Article: Supportive and Palliative Care
Original Article: Supportive and Palliative Care in Cancer
ORIGINAL ARTICLE: Supportive Care
Original Research Article
PEDIATRIC ONCOLOGY : Original Article
PEDIATRIC SECTION: Editorial
PEDIATRIC SECTION: Original Article
Pictorial CME, Haematological
Poetry in Oncology
Position Paper
QUEST FOR AN ANTIDOTE TO RADIATION TOXICITY : Editorial
QUEST FOR AN ANTIDOTE TO RADIATION TOXICITY : Original Article
RCC Practical Consensus Recommendations
Regional Article
Review Article
Review Article, Breast
Review Article, Gastro Intestinal
Review Article, Haematological
Review Article, International
Review Article, Nervous System
Review Consensus, Geriatric Oncology
SARCOMA : Original Article
SARCOMA Review Article
SOFT TISSUE SARCOMA : Original Article
South Asia update
SOUTH ASIAN UPDATE : An update
SOUTH ASIAN UPDATE : Original Article
TABACCO, THE MENACE : Original Article
THE CUTTING EDGE OF RADIOTHERAPEUTICS : Editorial
THE CUTTING EDGE OF RADIOTHERAPEUTICS : Original Article
THE GREAT DEBATE: Against HPV vaccine in cervical cancer
THE GREAT DEBATE: AGAINST IMATINIB AS THE FIRST LINE TKI CHOICE FOR CML
THE GREAT DEBATE: Editorial-HPV vaccine in cervical cancer
THE GREAT DEBATE: For HPV vaccine in cervical cancer
THE GREAT DEBATE: FOR IMATINIB AS THE FIRST LINE TKI CHOICE FOR CML
THE GREY-HAIRED CANCER PATIENT: Editorial
THE GREY-HAIRED CANCER PATIENT: Original Article
THE SKILLFUL SCALPEL: Editorial
THE SKILLFUL SCALPEL: Original Article
THE WAR ON MICROBES: Editorial
THE WAR ON MICROBES: Original Article
THROUGH THE MICROSCOPE : Original Article
THROUGH THE MICROSCOPE: Editorial
TREATMENT TOXICITY : Original Article
TRENDS IN HORMONAL THERAPY IN PROSTATE CANCER: Review Article
URO-ONCOLOGY : Original Article
View Point
Viewpoint
View/Download PDF
Original Article
Molecular
15 (
2
); 356-368
doi:
10.25259/SAJC_14_2026

Translate:

Detection of serum levels of human telomerase reverse transcriptase mRNA in non-alcoholic steatohepatitis related hepatocellular carcinoma in Sri Lanka

Author affiliations
Institute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo, Ragama, Sri Lanka
Department of Surgery, University of Kelaniya, Ragama, Sri Lanka
Department of Medicine, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka
Article History
Corresponding author(s)
Author image
Corresponding author: Asanka Sudeshini Hewage, Institute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo, Colombo, 03-00000, Sri Lanka. sudeshi@ibmbb.cmb.ac.lk
Article tools · PDF & citations

Abstract

Objectives:

A key driver gene implicated in hepatocellular carcinoma (HCC) is the upregulation of human telomerase reverse transcriptase (hTERT). Non-alcoholic steatohepatitis - related hepatocellular carcinoma (NASH-HCC) has emerged as one of the most prevalent HCC subtypes. However, studies on the clinical impact of hTERT expression levels from NASH-HCC patients in Sri Lanka are scarce. This study aimed to evaluate the serum levels of hTERT mRNA in patients with NASH-HCC in comparison to cirrhotic age, body mass index (BMI), and gender matched controls, and analyse the possible link between the hTERT mRNA expression levels and descriptive, clinical and tumour characteristics data of NASH-HCC patients.

Material and Methods:

Twenty - one participants were recruited, including 7 NASH-HCC test subjects, 7 cirrhotic age, BMI and gender matched controls and 7 healthy controls. mRNA extracted; cDNA was prepared using kit protocols with minor optimisations, while qPCR was run with the SYBR green method. Statistical Package for Social Science (SPSS) version 20 was used for the analysis, and data were presented as mean ± standard deviation (SD). Mann- Whitney U test was used to analyse the differences in hTERT mRNA between the NASH-HCC and cirrhotic matched-controls. Spearman’s rho test was used to evaluate the correlation between the hTERT mRNA levels and the descriptive, clinical, and tumour characteristics data. The p-value for all analyses was considered statistically significant if <0.05.

Results:

The analysis revealed a markedly elevated expression of hTERT mRNA in the NASH-HCC cohort, with a mean level of 9.11 ± 8.44, representing a sevenfold increase compared to the cirrhotic matched control cohort, which exhibited a mean expression level of 1.3 ± 1.49. Among the correlated parameters, only alanine aminotransferase (ALT) and tumour nodularity correlated with hTERT mRNA expression from NASH-HCC patients, suggesting a possible link between hTERT activity and disease severity.

Conclusion:

The significantly higher serum expression of hTERT in NASH-HCC patients, coupled with correlated ALT and tumour nodularity, signified its potential as a diagnostic biomarker for NASH-HCC. Further studies are recommended to evaluate the further link between hTERT mRNA expression levels and some of its genetic driving risk factors, such as pathogenic hTERT promoter SNPs and related transcription factors, using a larger sample size.

Keywords

  • Biomarker
  • Diagnosis
  • HCC
  • hTERT mRNA
  • NAFLD
  • NASH-HCC
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Liman UU, Hewage AS, de Silva S, Samarasinghe SM, Tennekoon KH, Siriwardana RC, et al. Detection of serum levels of human telomerase reverse transcriptase mRNA in non-alcoholic steatohepatitis related hepatocellular carcinoma in Sri Lanka. South Asian J Cancer. 2026;15:356-68. doi: 10.25259/SAJC_14_2026

INTRODUCTION

Liver cancer remains one of the most pressing global health challenges. It is the 6th most common cancer, ranking as the 5th most common cancer in men and the 9th most common cancer in women globally.[1] The International Agency for Research on Cancer (IARC), in collaboration with Global Cancer Observatory (GLOBOCAN) (2022), reported 20 million new cases of liver cancer and 9.7 million mortalities, with an estimated death risk of 1 in 9 for men and 1 in 12 for women.[2] In Asia, liver cancers accounted for 609,596 new cases, approximately 72.5% of the worldwide incidence, with an Age-Standardised Rate (ASR) of 11.6 per 100,000.[3-5] The most recent data show 33,243 new cancer cases, 19,145 deaths, and 86,508 prevalent cancer cases over five years in Sri Lanka.[4] In Sri Lanka, liver cancer ranks 20th in incidence and 15th in mortality, with 402 new cases and 380 deaths as at 2022.[4] Hepatocellular Carcinoma (HCC) is the most common primary liver cancer and one of the leading causes of cancer mortality globally.[6,7] HCC is more prevalent in subSaharan Africa and Eastern Asia, representing up to 80% of liver cancer cases worldwide.[8] Over the past 15 years, the incidence of HCC has been gradually increasing in Sri Lanka due to a lack of knowledge, poor diagnostic tools, and limited treatment choices.[9] The major risk factors that influence HCC development are alcohol abuse, viral infections such as chronic Hepatitis B and C, exposure to aflatoxins, and non-alcoholic fatty liver disease (NAFLD).[1,5,10-13] NAFLD, also known as metabolic dysfunction-associated steatotic liver disease (MASLD), is the most emerging risk factor of HCC that has a variety of sub-risk factors.[14-18] It is a spectrum and complex disease that ranges from benign or simple steatosis to the NASH-HCC stage. The increasing NAFDL incidence and its emerging sub-risk factors are replacing conventional risk factors like alcohol abuse and exposure to viral hepatitis B and C.[19] NAFLD is currently the most prevalent risk factor for HCC, with an overall estimate of 29% and exceeding 40% in some regions of Asia.[20] The prevalence of NAFLD varies widely across Asian regions because of the substantial diversity in race, socioeconomic status, and living environment.[21] Few studies were conducted on NAFLD-HCC/NASH-HCC in some Asian regions. For example, Southeast Asia (especially India, Pakistan, Sri Lanka, Bangladesh, and Nepal) receives less research despite being the region with the highest prevalence, while Singapore, Malaysia, and Thailand are leading in NAFLDHCC/NASH-HCC research.[22] Sri Lanka has had, indirectly, one of the highest rates of NAFLD in the South Asian region for more than a decade, affecting both adults and adolescents and raising the risk of diabetes considerably.[23] In Sri Lanka, 32.6% of adults in urban areas and 18% of individuals in rural areas have ultrasonically identified NAFLD annually.[23-25] Genetic predisposing factors, sedentary lifestyles, low health awareness, socioeconomic growth, wealth, urbanisation, and dietary westernisation may all contribute to the high prevalence of NAFLD in this region.[22]

NAFLD has various stages from simple steatosis of the liver to a chronic stage called non-alcoholic steatohepatitis -related hepatocellular carcinoma (NASH-HCC); however, it is challenging to clinically diagnose it at early stages. NASH-HCC is the final stage of NAFDL pathogenesis. At this stage, it is physiologically challenging to treat NAFLD. This is associated with late diagnosis and the impacts of several sub-risk factors acquired through the pathogenesis stages. One-third of the world's population is expected to be affected by NASH-HCC, with the projected incidence to rise to 56% in the next decade.[26,27] Lifestyle moderation could reduce the severity of NASH-HCC; however, genetic predisposition risk factors are difficult to regulate due to their association with the genetic information of an individual. Fortunately, early identification and understanding of the genetic predisposition factors their roles, and mechanisms in the progression of NAFLD to NASH-HCC may offer important treatment strategies. Although the pathophysiological mechanism of NASH-HCC is currently poorly understood. There is a high unmet clinical need for appropriate diagnostic, prognostic, and therapeutic options to tackle the emerging NASH-HCC epidemic.[28] The current gold standard methods of screening and diagnosis of NASH-HCC are ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI). However, these modalities have limited sensitivity and poor accuracy, are expensive for low-income patients, invasive due to diagnostic surgical procedures, and have a risk of complications.[27,29,30]

At present, there is/are no validated non-invasive molecular biomarkers available to allow for better NASH-HCC risk screening, diagnosis, and prediction.[27-29] Although alpha-fetoprotein (AFP) has been used for decades for HCC surveillance by traditional etiologists, making it a gold standard in clinical practice. The challenges of AFP are limited sensitivity and specificity for HCC detection, and a proportion of patients with advanced HCC do not have significant AFP secretion.[31,32] This suggests the difficulties in establishing broad guidelines for diagnosing NASH-HCC patients using AFP concentration, especially for patients at an early stage who do not have fibrosis and/or cirrhosis; instead, each patient is assessed based on the clinical presentation.[27,33] These limitations necessitate finding alternatives that will be more specific and sensitive for NASH-HCC screening, diagnosis, and prediction at an early stage, irrespective of the patient's clinical presentations. It is well established that cancer is a genetic disease where several genetic variations appear to alter the expression patterns of the key genes of affected proteins, such as enzymes, transporters, hormones, etc. Gene expression is a process where the genotype gives rise to the phenotype by investigating the amount of transcribed mRNA present in a biological system.[27,34] Gene expression analysis is crucial for identifying genes and understanding their potential effects on cellular processes and disease pathogenesis.[35] Considering proteins as the final products of gene expression responsible for determining the phenotypes and biological processes, their expression level detection can be used for cancer diagnosis, prognosis, and treatment prediction in a clinical setting.[36] However, gene expression studies are mostly conducted by quantifying messenger RNA (mRNA). This is due to the stability and efficiency of mRNA, which appears to be a key intermediate and regulator in controlling the expression of many proteins; its dysregulation has been associated with human diseases, including cancer, inflammatory diseases, and Alzheimer's disease.[27,37] Changes in mRNA expression profile in disease, and its correlation with clinical parameters, serve as clinically relevant biomarkers.[27,38] Hence, accurate determination of the mRNA levels is critically important in describing the biological, pathological, and clinical roles of genes in health and disease conditions.[38] An RNA-based gene expression study assay using the Northern Blot method was developed in 1977. Since then, there has been progress in this field.[27,39] Today, more sophisticated techniques are developed for gene expression studies, which include qPCR, RT-PCR, expression microarrays, and RNA sequencing (RNA-Seq), among others.[27,40] Understanding the expression landscape of key enzymes associated with NASH-HCC development is significantly advancing. Gene expression studies of some unique genes are found to link to the pathophysiology of NAFLD and NASH-HCC severity at the laboratory level. One key regulatory gene associated with NASH-HCC is human telomerase reverse transcriptase (hTERT). hTERT is the catalytic subunit of the telomerase complex. Over two decades, a correlative study between the expression of hTERT mRNA level and its activity suggested its potential as a candidate for the diagnosis of HCC.[41] This suggestion was based on the identified hTERT synthesis, which was under the control of hTERT mRNA, and the possibility observed was promising, as the noncancerous liver tissue with chronic liver diseases acquires HCC when the hTERT mRNA is positive.[41] Interestingly, about a decade ago, another study also reported the clinical importance of serum TERT mRNA in diagnosing HCC by developing a quantitative detection method.[42] Additionally, a comprehensive comparative study by Miura et al. proved that hTERT mRNA is superior to conventional HCC AFP, AFP-L3 and Des-gamma-carboxyprothrombin (DCP) markers in the diagnosis and recurrence of HCC at an early stage.[43] El-Mazny et al. also reported that serum hTERT mRNA correlates with tumour growth and has higher sensitivity and specificity than standard AFP for early viral and alcohol-based HCC diagnosis.[44] However, studies are scarce on hTERT mRNA quantification specifically from the NASH-HCC patients, which could be due to its current emergence. However, the previous studies offered insight into the applicability of hTERT mRNA levels for the diagnosis of NASH-HCC, since it is an emerging subtype of HCC. To our knowledge, no published research explicitly looked at the hTERT mRNA expression level from NASH-HCC patients using the cirrhotic matched-control related to healthy individuals in any region of the world, including Sri Lanka. Hence, this research aimed to be the first study that analysed the expression of the hTERT mRNA levels from the NASH-HCC patients and cirrhotic matched - control and healthy group, hoping to shed light on the potential of hTERT mRNA expression level as a screening or diagnostic biomarker for NASH-HCC patients. Detecting the hTERT mRNA expression levels in NASH-HCC patients may positively enhance the diagnosis of NASH-HCC and possibly reduce the late and less sensitive challenges associated with traditional HCC biomarkers. Additionally, this study further correlated the hTERT mRNA level with NASH-HCC patients' descriptive, clinical, and tumour characteristics data, ascertaining the potential and impact of correlations for NASH-HCC early diagnosis.

MATERIAL AND METHODS

Study subjects

This study comprised (n=21) participants: (n=7 NASH-HCC test subjects), (n=7 cirrhotic age, body mass index (BMI), and gender matched controls), and (n=7 healthy individuals) who were referred to North Colombo, teaching hospital, Ragama, Sri Lanka. NASH-HCC was diagnosed according to the established diagnostic criteria of the Asian Pacific Association for the Study of the Liver (APASL).[45] Informed consent forms were issued to the participants, and written informed consent was obtained from each willing participant. The ethical approval (ERC ID: P/230/11/2019) was granted by the Ethical Review Committee of the Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka. To select the NASH-HCC cohort, the following criteria were considered: the patients had no history of significant alcohol consumption, were found negative after viral hepatitis screening, had no clinical evidence of other metabolic liver diseases, and presented at least one NASH metabolic risk factor (obesity, type 2 diabetes, or dyslipidemia). All the qualified patients were ascertained to have NASH-HCC before the age of 60, with a mean age of 55 years. They were scanned using CT and MRI to affirm their liver disease status. Furthermore, AFP was confirmed to be above 400 µ/L, and the liver biopsy shows NASH-HCC histological evidence. The patients with NASH-cirrhosis but not at the NASH-HCC stage were selected as cirrhotic age, BMI, and gender matched controls. However, while selecting the cirrhotic age, BMI, and gender matched control, the effort was made to select only the patient at the first stage of cirrhosis, called Child-Pugh A stage. The healthy individuals' control group comprised individuals with no known liver-related disease. Individuals were further considered healthy when an ultrasound scan/ CT scan result did not show focal liver lesions or any liver-related malignancy. The same exclusion criteria were used for both NASH-HCC patients, cirrhotic age, BMI, and gender matched-control and healthy individuals. The excluded individuals were patients with indeterminate lesions, patients who underwent surgery for liver-related illnesses, patients with a history of other malignancies, and non-consenting patients.

Sample collection and storage

To ensure an RNase-free environment for the hTERT mRNA quantification, all glassware, PCR tubes, centrifuge tubes, and pipette tips in the box were treated with 0.1% (v/v) diethylpyrocarbonate (DEPC). 10 ml of the peripheral venous blood sample was collected in plain tubes by the medical team from the North Teaching Hospital, Ragama, Sri Lanka, by qualified nurses. A 5 mL aliquot was immediately transferred to an ethylenediaminetetraacetic acid (EDTA) coated tube and gently inverted several times to separate the plasma. The remainder (5 mL) was transferred to a plain tube to separate the serum. The blood samples were transported to the laboratory in an ice box. The collected blood samples were subjected to centrifugation at 900 g for 7 min at 4 ℃ to obtain cell-free serum and prevent a direct influence of lymphocytes. The obtained serum was carefully transferred into a new autoclaved Eppendorf tube without disturbing the red blood cells and stored at -80 ℃ until mRNA extraction.

Real-time quantitative reverse transcription (RT)-PCR for detecting the level of hTERT mRNA

The serum total RNA was extracted using Qiagen miRNeasy kit (Cat No: 217184, Qiagen) following the manufacturer’s instructions. After the extraction, the quantity of the extracted RNA was measured using a BioSpec-nanoUV-Vis spectrophotometer (A115746000094) and recorded in ng/µL. The step method was used for the quantification of hTERT mRNA. First, complementary DNA (cDNA) synthesis.

For each sample, a cDNA synthesis reaction, 100 ng of RNA input was used. The RNase-free water used depends on the concentration and volume of the RNA used to bring the total volume to 13.50 µL. Then, 1 µL of random primer (Cat. No. C118A) was added. This mixture was incubated at 70 °C for 5 minutes in a PCR machine. The mixture was immediately placed on ice, preventing the annealing of RNA single strands. To prepare the second cDNA synthesis mixture, all the RNA-primer hybrid mixture was transferred to the new 0.1 ml PCR tube, then 5 µL of Molony Murine Leukaemia Virus (MMLV) reaction buffer (Cat. No. M1701) was added, followed by 5 µL of dNTP (Cat. No. MBT078-1ML). Then 1 µL of MMLV reverse transcriptase (Cat. No. M1701) was added. Then 0.5 µL of an RNase inhibitor (Cat. No. N2611) was added, making the total volume 25 µL. The mixture was incubated at 37 °C for 60 minutes in a PCR machine to synthesise cDNA. Afterwards, the mixture was quickly transferred to the ice and kept for 3 minutes to stop the reaction before proceeding to the PCR reaction preparation. Secondly, the qPCR was performed using Qiagen 2x Quanti Nova SYBR Green PCR (Cat. no. 208052). The set of primers used is hTERTF: GGATGAAGCGGAGTCTGGA and hTERTR: CGGAAGAGTGTCTGGAGCAA, while the housekeeping gene (GAPDH) control primer set was: GAPDH-Fw, CGGAGTCAACGGATTTGGTCGTAT and GAPDH-Rv, AGCCTTCTCCATGGTGGTGAAGAC. There was significant optimisation of the qPCR protocol in this study. 10 µL of 2x Quant Inova SYBR Green PCR Master Mix was pipetted and transferred into 0.2 ml PCR tubes. Then, a primer concentration gradient was made with 0.6 µL (0.3 µM), 1 µL (0.5 µM), and 1.6 µL (0.8 µM) of 10 µM hTERTF primer. Then 2 µL of synthesised template cDNA was added, representing 10% of the total volume of 20 µL. Then, a primer concentration gradient was made with 0.6 µL (0.3 µM, 1 µL (0.5 µM), and 1.6 µL (0.8 µM) of 10 µM hTERTR primer was added. Then, 4.8 µL of RNase-free water was added to make it 20 µL in total. The mixture was briefly stirred to ensure an even mixture of the components.

The whole mixture was transferred to the well of the qPCR strips with (Cat No. TLS0801) and covered with a lid (Cat No. TCS0803). To optimise the annealing/extension temperatures for the primers, a gradient of 60 °C, 62 °C, and 64 °C was tested, and the time was extended to 90 seconds instead of 10 seconds for amplification of hTERT cDNA with hTERTF and hTERTR. This optimisation was considered due to the high GC content of the targeted region within the hTERT gene. All the selected temperatures produced remarkable Ct values. However, 62 °C produced more prominent Ct values and sharp melt peaks compared to the 60 °C and 64 °C gradients. Therefore, 62 °C was selected as the combined annealing and extension temperature for all subsequent samples. The number of cycles was increased from 40 to 60 cycles, which yielded more pronounced peaks.

Statistical analysis

A Statistical Package for Social Science (SPSS) version 20 was used for the analysis of data, which some were summarized as mean and standard deviation (SD). The Mann-Whitney U test was used to analyse the differences in hTERT mRNA between the NASH-HCC and cirrhotic age, BMI, and gender matched controls. The p-value was considered significant if <0.05. Spearman’s rho test was used to analyse the correlation between the hTERT mRNA and the descriptive, clinical investigation, and tumour characteristics data at <0.05.

RESULTS

The hTERT primer pairs produced an approximately 131 bp product size while the GAPDH yielded approximately 308 bp amplicons, which were confirmed with gel electrophoresis and depicted in Figure 1. After successful amplification confirmation and quantification of both the hTERT target and GAPDH, the Ct values were obtained for each sample in each cohort, and calculations of hTERT mRNA relative expression were performed using the Livak method. The NASH-HCC cohort had high expression of hTERT mRNA, with an average mean level of 9.11 ± 8.44, about 7-fold compared to a cirrhotic age-, BMI-, and gender-matched control cohort, which exhibited a mean expression level of 1.3 ± 1.49. The hTERT mRNA expression level of the NASH-HCC patients correlated with alanine aminotransferase (ALT) and tumour nodularity at p <0.05, while other parameters did not reveal a correlation.

Gel image for confirmation of GAPDH and hTERT amplification. 8 µL of each strip of cDNA product in the strip containing the NASH-HCC 02 sample were loaded. Lane 1 is DNA ladder (1kb ladder), lane 2 is GAPDH and lane 3 is hTERT. The GAPDH with 308 bp is just below the 500 bp band of the ladder while the hTERT with 131 bp is at the button of the gel. The blurry bands were due to the larger volume loaded as well as good amplification of both the GAPDH and hTERT gene targeted region. From this image, it can be affirmed that both the GAPDH and hTERT gene target were specifically amplified with high accuracy. hTERT: Human telomerase reverse transcriptase, cDNA: Complementary DNA, NASH-HCC: Non-alcoholic steatohepatitis - related hepatocellular carcinoma, GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.
Figure 1: Gel image for confirmation of GAPDH and hTERT amplification. 8 µL of each strip of cDNA product in the strip containing the NASH-HCC 02 sample were loaded. Lane 1 is DNA ladder (1kb ladder), lane 2 is GAPDH and lane 3 is hTERT. The GAPDH with 308 bp is just below the 500 bp band of the ladder while the hTERT with 131 bp is at the button of the gel. The blurry bands were due to the larger volume loaded as well as good amplification of both the GAPDH and hTERT gene targeted region. From this image, it can be affirmed that both the GAPDH and hTERT gene target were specifically amplified with high accuracy. hTERT: Human telomerase reverse transcriptase, cDNA: Complementary DNA, NASH-HCC: Non-alcoholic steatohepatitis - related hepatocellular carcinoma, GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.

Analysis of GAPDH and HTERT primers efficiency for qPCR

Following the successful qPCR of the housekeeping gene (GAPDH) and hTERT gene from the cDNA samples, various parameters were obtained from the output, including the Ct value, amplification plot, and melt peak. The Ct value is the significant cycle of amplification that crosses the set threshold of the qPCR. Figure 2 depicts the amplification plots of GAPDH and hTERT mRNA expression.

Amplification plot for housekeeping gene (GAPDH) and target (hTERT mRNA) from cDNA of a representative sample. However, the amplification crossed the threshold (Ct) after the 28 cycles which took approximately 1 hour. The green colour plot is for the housekeeping gene (GAPDH), while the orange colour plot is the target (hTERT). The plot crossed the threshold at cycle 33.184 cycle for GAPDH and at cycle 28.018 for hTERT gene in this reaction. hTERT: Human telomerase reverse transcriptase, mRNA: Messenger RNA, cDNA: Complementary DNA, GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.
Figure 2: Amplification plot for housekeeping gene (GAPDH) and target (hTERT mRNA) from cDNA of a representative sample. However, the amplification crossed the threshold (Ct) after the 28 cycles which took approximately 1 hour. The green colour plot is for the housekeeping gene (GAPDH), while the orange colour plot is the target (hTERT). The plot crossed the threshold at cycle 33.184 cycle for GAPDH and at cycle 28.018 for hTERT gene in this reaction. hTERT: Human telomerase reverse transcriptase, mRNA: Messenger RNA, cDNA: Complementary DNA, GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.

Amplification plot analysis

The amplification plot typically represents the increase in fluorescence of SYBR green dye over the qPCR cycles, which usually begins to rise exponentially as the target DNA is initially amplified. To visualise the real-time progress of the reaction, the amplification curve was observed after the first five minutes of the reaction.

Melt curve analysis

It is crucial to analyse the melt curve of both GAPDH and hTERT primers to ascertain their specificity. Figure 3 below depicts the melt peaks of the GAPDH and hTERT primers.

Melt curve peak of GAPDH and hTERT from cDNA of representative sample. A clear peak of 79 ℃ was observed in this reaction. It aligns with the theoretical value for the GAPDH sequence melt peak which is within the range of 70 °C to 85 °C under standard qPCR conditions. hTERT showed a melt peak temperature of 84 °C which is above the annealing temperature of the hTERT primers. Both primers amplified their targeted region, justifying the specificity of GAPDH and hTERT primers. hTERT: Human telomerase reverse transcriptase, cDNA: Complementary DNA, GAPDH: Glyceraldehyde-3-phosphate dehydrogenase, qPCR: Quantitative polymerase chain reaction.
Figure 3: Melt curve peak of GAPDH and hTERT from cDNA of representative sample. A clear peak of 79 ℃ was observed in this reaction. It aligns with the theoretical value for the GAPDH sequence melt peak which is within the range of 70 °C to 85 °C under standard qPCR conditions. hTERT showed a melt peak temperature of 84 °C which is above the annealing temperature of the hTERT primers. Both primers amplified their targeted region, justifying the specificity of GAPDH and hTERT primers. hTERT: Human telomerase reverse transcriptase, cDNA: Complementary DNA, GAPDH: Glyceraldehyde-3-phosphate dehydrogenase, qPCR: Quantitative polymerase chain reaction.

DISCUSSION

This study quantified the serum expression levels of hTERT mRNA from NASH-HCC patients by comparing them with cirrhotic age, BM, and gender-matched control cohort and healthy group. It further explored the relationship between hTERT mRNA expression from NASH-HCC patients' serum and descriptive, clinical, and tumour characteristics data as presented in Tables 1 and 2, respectively. In this study, amplification of the hTERT targeted region was not achieved using the hTERT primer pairs following the manufacturer’s kit protocol, which necessitated troubleshooting and optimisation of the protocol. Several factors could lead to the failure of qPCR, including RNA/cDNA concentration, primer concentration, base composition, expected product length, the product GC content, annealing temperature, annealing and extension time, and the number of reaction cycles, among others.[46] Insufficient annealing temperature can result in the total absence of product or non-specific DNA amplification with the appearance of smears when confirmed on agarose gels.[47,48]

Table 1: Descriptive data of the NASH-HCC patients and cirrhotic matched control
Descriptive data NASH-HCC (n = 7) Cirrhosis (n = 6)
*Age (Years) 55.14 ± 13.39 53.50 ±10.73
*BMI (kg/m2) 26.48 ± 4.58 25.11 ± 5.38
Gender
  Male 6 4
  Female 1 2
Data are presented as mean ± SD. NASH-HCC: Non-alcoholic steatohepatitis - related hepatocellular carcinoma, SD: Standard deviation, BMI: Body mass index.
Table 2: Clinical and tumour characteristic data of the NASH-HCC patients
Parameter   Value
*AST (U/L) 46.71 ± 33.33
*ALT (U/L) 41.43 ± 24.80
*Bilirubin (mg/dl) 2.06 ± 1.99
*Albumin (g/dl) 3.39 ± 1.52
*IRN 0.89 ± 0.40
Tumour characteristic data
*Tumour size (cm) 7.29 ± 6.97
Nodularity
Single
Multiple
Other
Categorized
5
1
1
Data are presented as mean ± SD. NASH-HCC: Non-alcoholic steatohepatitis - related hepatocellular carcinoma, ALT: Alanine aminotransferase, SD: Standard deviation, INR: International normalized ratio, AST: Aspartate aminotransferase.

A representative sample was used for troubleshooting by optimising the hTERT primer concentrations and qPCR cycle conditions. Prominent amplification plots and melt peaks with Ct values were obtained after this troubleshooting and optimisation, as shown in Figures 2 and 3, respectively.

The hTERT mRNA expression was compared among each member of the NASH-HCC patients and cirrhotic controls separately, as shown in Table 3. This was done in order to observe the absolute variation of the relative hTERT mRNA expression among the NASH-HCC patients’ samples and cirrhotic controls despite being diagnosed using similar clinical parameters as shown in Figures 4 and 5, respectively.

Table 3: Calculated 2-^ΔΔCt of each sample from NASH-HCC patients and cirrhotic matched control
NASH-HCC 2-^ΔΔCt Cirrhosis 2-^ΔΔCt
NASH-HCC 02 0.20 Cirr 06 0.11
NASH-HCC 18 16.56 Cirr 16 0.24
NASH-HCC 08 3.76 Cirr 18 1.04
NASH-HCC 38 8.75 Cirr 14 0.12
NASH-HCC 33 23.75 Cirr 10 3.94
NASH-HCC 37 8.63 Cirr 25 2.85
NASH-HCC 07 2.13 Cirr 09 1.10

NASH-HCC: Non-alcoholic steatohepatitis - related hepatocellular carcinoma

Dot plot representing the hTERT relative expression of each NASH-HCC sample. The dot plot representing each NASH-HCC sample clearly described variation of hTERT mRNA expression with NASH-HCC sample with ID 33 and sample with ID 2 has the lowest expression. NASH-HCC: Non-alcoholic steatohepatitis - related hepatocellular carcinoma, hTERT: Human telomerase reverse transcriptase, mRNA: Messenger RNA.
Figure 4: Dot plot representing the hTERT relative expression of each NASH-HCC sample. The dot plot representing each NASH-HCC sample clearly described variation of hTERT mRNA expression with NASH-HCC sample with ID 33 and sample with ID 2 has the lowest expression. NASH-HCC: Non-alcoholic steatohepatitis - related hepatocellular carcinoma, hTERT: Human telomerase reverse transcriptase, mRNA: Messenger RNA.
Dot plot representing the hTERT relative expression of each cirrhotic age, BMI, and matched controls. The cirrhotic matched sample with ID 10 had the highest hTERT mRNA expression, while the sample with ID 6 had the lowest expression. hTERT: Human telomerase reverse transcriptase, BMI: Body mass index, mRNA: Messenger RNA.
Figure 5: Dot plot representing the hTERT relative expression of each cirrhotic age, BMI, and matched controls. The cirrhotic matched sample with ID 10 had the highest hTERT mRNA expression, while the sample with ID 6 had the lowest expression. hTERT: Human telomerase reverse transcriptase, BMI: Body mass index, mRNA: Messenger RNA.

From the NASH-HCC patients, NASH-HCC 33 showed the highest hTERT mRNA expression level of 23.75. While for the cirrhotic matched-control cirrhotic, patient ID 10 revealed the highest hTERT mRNA expression among the cirrhotic matched -controls as observed in Table 3. This might be related to advanced hepatocyte damage in these patients. Another possible reason is that only NASH-HCC 33 had multiple nodularity, which could also suggest why it had the highest hTERT expression level, as each nodule may have contributed to the overall hTERT mRNA expression. This agreed with the findings of that suggested that the induction of hTERT mRNA is an important early event and its measurement by qPCR is a useful tool to detect malignant tendencies in hepatic nodules.[49] Additionally, NASH-HCC 33 is the second patient with a high ALT level, possibly another reason why NASH-HCC 33 had a high hTERT mRNA expression level, as both are indicators of NASH-HCC pathogenesis. Although this could not be sufficient to strongly justify the reason for the highest expression of hTERT mRNA in the NASH-HCC 33 patients’ sample, it could be a possible reason for variation with other NASH-HCC patients within the same cohort.

Generally, the variations observed in hTERT mRNA expression levels from all NASH-HCC patients could result from several factors. It could be due to inherent variations of genomic, transcriptomic, epigenetic, proteomic, and metabolomic profiles or physiological differences among the patients. For instance, a recent metabolomic and transcriptomic integration study reveals that up to 267 metabolic profiles of hepatocellular carcinoma significantly alter among the patients.[50] Another recent study by Ahmed et al. (2023) on NASH-HCC serum metabolic profiling showed a panel of twenty metabolites with 10% False Discovery Rate and p ≤ 0.05 in both targeted and non-targeted analysis that could play a role in NASH-HCC variations.[51] Interestingly, the actual statistical correlation analysis between the mean level of hTERT mRNA and the descriptive, clinical, and tumour characteristics data that comprised the whole sample size could give a more reliable explanation of the variations in hTERT mRNA of the study cohorts.

Significant variation of hTERT mRNA expression reported in Table 3 among the cirrhotic matched controls was observed despite the critical selection of Child-Pugh A stage among the cirrhotic matched controls. A Child-Pugh A stage of cirrhosis is the most suitable NASH-HCC control, as it represents a significant distance in clinical features to NASH-HCC stage compared to the Child-Pugh B stage with 7 to 9 points (moderately impaired hepatic function), or the Child-Pugh C stage with 10 to 15 points (advanced hepatic dysfunction).[52-54] Selecting the Child-Pugh A stage of cirrhotic stage in this study was the most suitable option as it was expected to yield a moderate view of the impact of hTERT mRNA expression levels in the progression of NAFLD from the very early cirrhotic stage to NASH-HCC stage, as other confounding risk factors were ruled out, including hepatitis virus-positive patients and patients consuming alcohol above the normal range. Clinically, cirrhosis is considered a risk factor that drives HCC since up to 90% of HCCs arise in a background of cirrhosis.[55] The highest hTERT mRNA expression observed from Cirrhotic ID 10 is possibly associated with the advanced cirrhotic stage, despite the Child-Pugh A stage being used in selecting the cirrhotic matched controls.

Another reason could be the possession of predisposing risk factors that drive hTERT mRNA expression. This could be hTERT gene amplification , hTERT promoter mutations, or chromosome translocation.[56] Like in the other HCC etiologist, accumulation of these predisposing driving factors, particularly hTERT overexpression, can maintain the cirrhotic hepatocytes' telomeres from cell death, which ultimately renders them to exhibit immortality capability. Since in this study, the confounding risk factors that drive hTERT overexpression were not analysed, it will be difficult to establish why NASH-HCC and the cirrhotic matched controls revealed variations in hTERT mRNA expression. Another limitation is that no study specifically addresses the individual variations within the NASH-HCC patients and cirrhotic matched-control cohorts. However, observing individual hTERT expressions and presenting these variations in Table 3 as well as Figures 4 and 5 provided a clear understanding of inherent variations due to either genetic predisposing factor, clinicopathological conditions, and environmental factors that probably drive the variations at NAFLD stages.

Nevertheless, to achieve a more holistic understanding of the hTERT mRNA expression levels between NASH-HCC patients and the cirrhotic matched-control cohort, a comparative analysis was performed and presented in Table 4. This is because gene expression profiles can be directly compared within or between species, especially when they are derived from matching cells/organs.[57] In this study, the NASH-HCC cohort had hTERT mRNA expression of 9.11 ± 8.44, which was approximately 7-fold higher compared to the cirrhotic matched - control cohort with a mean of 1.34 ± 1.49 at p < 0.05 [Table 4]. The box plot graphical representation in Figure 6 represents the variation of the mean of hTERT mRNA expression between the NASH-HCC cohort and the cirrhotic matched control. From Figure 6, both the NASH-HCC cohort and the cirrhotic matched-control fell within the quartile ranges in the box plot, with NASH-HCC having the highest plot. No outlier was recorded among the sample in the cirrhotic matched control cohort following the outlier calculation formula as shown in Table 5. NASH-HCC patients have higher hTERT mRNA expression levels than cirrhotic control groups, potentially due to the specific or multicomplex driving factors that influence hTERT mRNA overexpression, which in turn pushes NASH-HCC. Among the most reported risk factors driving hTERT mRNA expression are c-Myc overexpression, p53 dysfunction, and TERT promoter mutations, among others.[58-60]

Table 4: 2-^ΔΔCt mean values of NASH-HCC patients and cirrhotic matched control cohorts
Cohort Mean ± SD of 2-^ΔΔCt
NASH-HCC 9.11 ± 8.44
Cirrhosis 1.34 ± 1.49

NASH-HCC: Non-alcoholic steatohepatitis - related hepatocellular carcinoma, SD: Standard deviation.

Table 5: Box plot output for hTERT mRNA expression between NASH-HCC patients and cirrhotic matched controls
Cohorts Mean ± SD Min Q1 Q2 (Median) Q3 Max
NASH- HCC 9.11 ± 8.44 0.20 2.13 8.63 16.56 23.75
Cirrhosis 1.34 ± 1.49 0.11 0.12 1.03 2.84 3.94

hTERT: Human telomerase reverse transcriptase, NASH-HCC: Non-alcoholic steatohepatitis - related hepatocellular carcinoma, mRNA: Messenger RNA, SD: Standard deviation.

Box plot representing the differences in hTERT mRNA expression between NASH-HCC patients and cirrhotic matched - control. NASH-HCC cohort had highest mean hTERT mRNA expression compared to cirrhotic age, BMI and gender matched control. hTERT: Human telomerase reverse transcriptase, NASH-HCC: Non-alcoholic steatohepatitis - related hepatocellular carcinoma, mRNA: Messenger RNA, BMI: Body mass index.
Figure 6: Box plot representing the differences in hTERT mRNA expression between NASH-HCC patients and cirrhotic matched - control. NASH-HCC cohort had highest mean hTERT mRNA expression compared to cirrhotic age, BMI and gender matched control. hTERT: Human telomerase reverse transcriptase, NASH-HCC: Non-alcoholic steatohepatitis - related hepatocellular carcinoma, mRNA: Messenger RNA, BMI: Body mass index.

Some previous studies reported variations of hTERT mRNA expression in HCCs from other etiologies than cirrhotic controls. For instance, about two decades ago, Miura et al. reported high expression of hTERT mRNA from 70 of 78 (89.7%) HCC patients in comparison to 7 of 10 (70.0%) cirrhotic samples, suggesting high expression of hTERT mRNA as a potential biomarker for HCC diagnosis.[61] Furthermore, another study on the hTERT mRNA level reported significant hTERT mRNA in HCC cancerous tissues compared to other types of tissue, and its level correlated with telomerase activity.[62] Another study by Miura et al. demonstrated the hTERT mRNA in HCC patients and suggested its clinical importance in diagnosing HCC.[42] Additionally, a comprehensive study found serum hTERT mRNA to have higher mean values in patients with HCC than in those with cirrhotic liver disease.[63] Further comparative study by El-Mazny et al.,[44] using Egyptian HCC patients, revealed that the mean hTERT-mRNA expression in HCC patients was significantly higher than in both cirrhotic patients and healthy controls, suggesting hTERT-mRNA to be a superior biomarker for HCC diagnosis, especially when coupled with AFP. Additionally, Miura et al. also reported that hTERT mRNA expression showed stepwise upregulation with disease progression, and the quantification was significantly higher in HCC than in cirrhotic controls at (p < 0.001) and (p < 0.01) levels, respectively.[43] One of the most relevant studies reported a higher expression of serum TERT mRNA from non-alcoholic HCC than cirrhotic patients and suggested hTERT mRNA as a sensitive biomarker for HCC for early HCC diagnosis.[44] Another similar study by Raouf et al. reported that the mean level of hTERT mRNA expression in HCC patients was significantly higher than in cirrhotic patients (p < 0.01).[64] Recently, Lombardo et al. reported more than a 300-fold relative increase in TERT expression from NAFLD-HCC cohorts in comparison to healthy controls.[65] Jang et al. also confirmed that hTERT expression was positively correlated with tumour differentiation and disease progression in HCC.[66]

However, while some of these studies well defined the cofounding factors and aetiology of the HCC patients used, some did not. For instance, El-Manzy et al. reported the higher expression of hTERT mRNA in HCC compared to cirrhotic liver without highlighting the actual HCC aetiology.[44] Another recent study on Vietnamese-confirmed HCC patients revealed that the abundance of hTERT mRNA in the HCC groups was significantly higher than that in the liver cancer group (P < 0.01) without a clear identity of the patient's HCC aetiology.[67] In contrast, our study applied stringent inclusion and exclusion criteria for selecting the NASH-HCC patients and cirrhotic matched-control cohort in order to have a plausible conclusion regarding the impact and variation in hTERT mRNA expression and NASH-HCC development as well as potentially a diagnostic biomarker for NASH-HCC diagnosis. Additionally, most of the previous comparative studies on hTERT mRNA expression between HCC and cirrhotic patients related to healthy controls used hTERT gene copy number quantification. While gene copy number quantification can significantly reveal whether a gene is amplified (increased copies) or deleted (decreased copies), it does not always reflect the actual mRNA transcript of that gene. This was also suggested by Oh et al., who reported that hTERT gene dosage is not the sole mechanism regulating hTERT expression in hepatocarcinogenesis.[49] However, main mRNA transcript level quantification mostly provides an indirect measure of gene activity at the transcriptional level, which is essential for understanding dynamic changes in gene expression in response to the disease progression, including NASH-HCC. Interestingly, in this study, the hTERT mRNA level qPCR quantification method was used, not copy number; therefore, coupling this study with a predisposing driving risk factor that drives hTERT gene overexpression from NASH-HCC patients may yield a more holistic and promising result regarding the potential application of hTERT mRNA expression level for early diagnosis of NASH-HCC. Literarily, the mean hTERT mRNA expression in NASH-HCC is about 6-fold of that in cirrhosis age-matched controls, as shown in Table 4 and Figure 6. This suggests the cirrhotic stage itself is a risk factor for NASH-HCC pathogenesis. This agrees with E. Bugianesi's findings, who reported that cirrhosis is a significant risk of early HCC development.[68] Although the emphasis was given to hTERT mRNA expression in this study, the progression of NASH-cirrhosis to NASH-HCC, as it falls within the NAFLD stages, could encompass all the hypothetical hits and the emerging risk factors of NAFLD. The risk factors include lifestyle, eating habits, metabolic dysregulation (such as insulin resistance and lipid metabolism abnormalities), oxidative stress, inflammation, genetic factors, and epigenetic modifications, among others. These hits are not mutually exclusive, hence making NASH-cirrhosis progression to NASH-HCC more complex. Furthermore, coupling the NASH-HCC patients' descriptive, clinical, and tumour characteristic parameters could shed more light on the justification of hTERT mRNA expression as a suitable and potential molecular biomarker for NASH-HCC diagnosis, as reported in Table 6. Among the correlated parameters with hTERT mRNA are age, BMI, ALT, AST, albumin, bilirubin, International Normalised Ratio (INR), tumour size, and tumour nodularity at p <0.05. Of all the correlated parameters, only ALT and nodularity correlated with hTERT mRNA expression. Recently, Natarajan et al. reported that patients with hepatic steatosis with high-level ALT are at high risk of NAFLD/NASH-HCC.[69] However, one previous study contradicted this study as they found no correlation between ALT and hTERT expression in the HCC patient serum at a p < 0.05 level.[61] Another study revealed the absence of correlation between ALT patients and hTERT mRNA expression from HCC patients.[44] Although ALT is an enzyme predominantly found in the liver and in smaller amounts in other tissues such as the kidneys, heart, and muscle cells.[70] Some of the NASH-HCC patients recruited for this study have ALT above the international unit (IU), while some had an average range. Traditionally, ALT has low concentrations in skeletal muscle and the kidney, and an increase in ALT serum levels somehow suggests more specific liver damage.[71,72] An increase in ALT serum levels literally indicates definite liver cell injury due to many causes.[69] It is obvious that any process that leads to loss of hepatocyte membrane integrity or necrosis could result in the release of ALT in high concentrations in the plasma.[73] Although the elevation of serum ALT concentration is sensitive to test for liver integrity, it is not specific for measuring hepatocellular injury.[74] However, the correlation between ALT and hTERT mRNA found in this study suggests their link in diagnoses of NASH-HCC, as hTERT is crucial for hepatocyte immortality while ALT clinically reflects the status of liver damage and inflammation. Furthermore, the observed positive correlation between serum ALT and hTERT mRNA expression in this study aligns with the CT result, which revealed a larger tumour size in most of the NSH-HCC patients, signifying liver damage. In this study, tumour nodularity correlated with hTERT mRNA expression. This agrees with the fact that cancer is characterised by abnormal cell growth and the presence of an extra mass of tissue, especially at the advanced stage.[75] A nodularity is a health condition where a nodule grows beneath the skin, in the organ or tissue.[76] Correlating nodularity of the NASH-HCC patients with their hTERT mRNA expression is crucial, as it was reported to positively reveal information regarding the tumour stage and size. It has been reported that the overexpression of hTERT occurs at early premalignant stages in regenerative nodules.[77] Although, till now, no study has correlated tumour nodularity and hTERT mRNA expression from NASH-HCC, the study agrees with the study by Miura et al., which revealed a positive correlation between nodularity and hTERT mRNA expression at p< 0.05 from viral HCC aetiology.[42] Since nodularity literally refers to the number of nodules, its correlation with hTERT mRNA may suggest their correlative influence in NASH-HCC patients. A study suggested that inner nodules represent a step further along the pathway of tumour progression.[78] Furthermore, nodularity could be an independent driving factor that may influence NASH-HCC through proliferative activity.

Table 6: Correlation of descriptive, clinical and tumour characteristics data and hTERT mRNA expression in the NASH-HCC patients
Descriptive/clinical data p-value
Age range (28-66 years) 0.726
BMI (kg/m2) 0.702
AST (U/L) 0.655
ALT (U/L) 0.023‡
Bilirubin (mg/dl) 0.818
Albumin (mg/dl) 0.253
IRN 0.148
Tumour size (cm) 0.760
*Nodularity 0.034‡
Categorised data. ‡ Data that significantly correlated with hTERT mRNA expression in the NASH-HCC cohort. p < 0.05 is statistically significant. hTERT: Human telomerase reverse transcriptase, NASH-HCC: Non-alcoholic steatohepatitis - related hepatocellular carcinoma, mRNA: Messenger RNA, BMI: Body mass index, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, INR: International normalised ratio

TAKE HOME MESSAGE

This study revealed NASH-HCC patients had high expression of hTERT mRNA with a mean level of 9.11 ± 8.44, compared to cirrhotic age, BMI and gender matched control, which exhibited a mean expression level of 1.3 ± 1.49, reflecting an estimate of sevenfold expression of the hTERT gene in NASH-HCC patients. The correlation section of this study revealed dynamic relationships of NASH-HCC patient description data (age and BMI), clinically investigated (AST, ALT, bilirubin, albumin and International Normalised Ratio) and tumour characteristics data (tumour size and nodularity) with hTERT mRNA expression levels. Of all the correlated parameters, only ALT and tumour nodularity showed a correlation with hTERT mRNA expression. This could be a result of confounding genetic driving factors and physiological conditions associated with NASH-HCC patients. However, considering the small sample size and being the first study to be conducted in Sri Lanka, it is recommended that more studies to be conducted with similar study criteria in larger cohorts across the country to give more comprehensive data in establishing the potentiality of hTERT mRNA as a non-invasive diagnostic marker for NASH-HCC to contribute in reducing its burden as a global health threat due its current increases in incidence, prevalence, and mortality rates. Additionally, it is recommended that the main predisposing factors influencing hTERT gene overexpression, such as hTERT rs1242535815 and rs1561215364 SNPs, epigenetic factors, miRNAs, and related transcription factors like p53, should be coupled when studying hTERT mRNA level in the future. Evaluating the relationship between hTERT mRNA levels and these risk factors within the same NASH-HCC patient sample may provide more holistic and promising results that will be used in the prediction of hTERT mRNA as a potential biomarker for early NASH-HCC diagnosis.

Ethical approval:

The research was approved by the Ethical Review Committee, Faculty of Medicine, University of Kelaniya, Number P/230/11/2019, dated 25th November 2019.

Declaration of patient consent:

The authors certify that they have obtained all appropriate participants consent.

Conflicts of interest:

There are no conflicts of interest.

Use of artificial intelligence (AI)-assisted technology for manuscript preparation:

The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript, and no images were manipulated using AI.

Financial support and sponsorship: Queen Elizabeth Commonwealth Scholarships research support grant.

References

  1. . Diet, nutrition, physical activity and cancer: A global perspective. Continuous Update Project Expert Report 2018. Available from: https://dietandcancerreport.org [Last accessed 2025 Mar 23]
    [Google Scholar]
  2. , , , , , , et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63.
    [CrossRef] [PubMed] [Google Scholar]
  3. , . Changes in the epidemiology of hepatocellular carcinoma in Asia. Cancers. 2022;14:4473.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , , , , , et al. Global Cancer Observatory: Cancer Today. . Lyon, France: International Agency for Research on Cancer; Available from: https://gco.iarc.who.int/today [Last accessed 2025 Mar 23]
    [Google Scholar]
  5. , , . Hepatocellular carcinoma: Old and emerging therapeutic targets. Cancers. 2024;16:901.
    [CrossRef] [PubMed] [Google Scholar]
  6. , , , , , , et al. Latest advances in hepatocellular carcinoma management and prevention through advanced technologies. Egypt Liver J. 2024;14:2.
    [CrossRef] [Google Scholar]
  7. . Hepatocellular carcinoma (HCC) . Medscape. Available from: https://emedicine.medscape.com/article/197319-overview [Last accessed 2025 Mar 23]
    [Google Scholar]
  8. . Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. J Liver Cancer. 2024;24:62-70.
    [CrossRef] [PubMed] [Google Scholar]
  9. , , , , , , et al. Cryptogenic cirrhosis is the leading cause for listing for liver transplantation in Sri Lanka. Indian J Gastroenterol. 2013;32:397-9.
    [CrossRef] [PubMed] [Google Scholar]
  10. , . Obesity, inflammation, and liver cancer. J Hepatol. 2012;56:704-13.
    [CrossRef] [PubMed] [Google Scholar]
  11. , , , , , , et al. Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: A nested case-control study based on Italian healthcare utilization databases. Pharmacoepidemiol Drug Saf. 2015;24:771-8.
    [CrossRef] [PubMed] [Google Scholar]
  12. , , , , , , et al. Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors. Hepatol Commun. 2018;2:718-31.
    [CrossRef] [PubMed] [Google Scholar]
  13. , , , . Hepatocytes: A key role in liver inflammation. Front Immunol. 2023;13:1083780.
    [CrossRef] [PubMed] [Google Scholar]
  14. , , . Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2018;69:268-79.
    [CrossRef] [PubMed] [Google Scholar]
  15. , , , , . Genetics, immunity and nutrition boost the switching from NASH to HCC. Biomedicines. 2021;9:1524.
    [CrossRef] [PubMed] [Google Scholar]
  16. , , , , , , et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542-56.
    [CrossRef] [PubMed] [Google Scholar]
  17. , , . Metabolic-associated steatotic liver disease (MASLD): A new term for a more appropriate therapy in pediatrics? Pediatr Rep. 2024;16:288-99.
    [CrossRef] [PubMed] [Google Scholar]
  18. , . From NAFLD to MASLD: Updated naming and diagnosis criteria for fatty liver disease. J Lipid Res. 2025;65:100485.
    [CrossRef] [PubMed] [Google Scholar]
  19. . Evolving global etiology of hepatocellular carcinoma (HCC): Insights and trends for 2024. J Clin Exp Hepatol 2024
    [CrossRef] [PubMed] [Google Scholar]
  20. , , , , . Asian perspective on NAFLD-associated HCC. J Hepatol. 2022;76:726-34.
    [CrossRef] [PubMed] [Google Scholar]
  21. , , . Changing clinical management of NAFLD in Asia. Liver Int. 2022;42:1955-68.
    [CrossRef] [PubMed] [Google Scholar]
  22. , . Nonalcoholic fatty liver disease in South Asia. Euroasian J Hepatogastroenterol. 2016;6:154-62.
    [CrossRef] [PubMed] [Google Scholar]
  23. , , , , , , et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol. 2009;24:1284-8.
    [CrossRef] [PubMed] [Google Scholar]
  24. , , , , , , et al. Non-alcoholic fatty liver disease in a rural, physically active, low-income population in Sri Lanka. BMC Res Notes. 2011;4:513.
    [CrossRef] [PubMed] [Google Scholar]
  25. , , , , , , et al. Incidence and risk factors for non-alcoholic fatty liver disease among adults: A 7-year follow-up study in an urban Sri Lankan community. Liver Int. 2017;37:1715-22.
    [CrossRef] [PubMed] [Google Scholar]
  26. , , , . From non-alcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC): Epidemiology, incidence, predictions, risk factors, and prevention. Cancers (Basel). 2023;15:5458.
    [CrossRef] [PubMed] [Google Scholar]
  27. , , , , , , et al. Pathogenic effects of telomerase reverse transcriptase (TERT) promoter mutations in non-alcoholic steatohepatitis-related hepatocellular carcinoma and its potential as a diagnostic biomarker. Egypt J Med Hum Genet. 2025;26:111.
    [CrossRef] [Google Scholar]
  28. , . Chronic liver disease In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; . Available from: https://www.ncbi.nlm.nih.gov/books/NBK559285/ [Last accessed 2025 Mar 23]
    [Google Scholar]
  29. , , , . NAFLD and NAFLD-related HCC: Emerging treatments and clinical trials. Int J Mol Sci. 2025;26:306.
    [CrossRef] [PubMed] [Google Scholar]
  30. , . Non-alcoholic steatohepatitis (NASH) In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; . Available from: https://www.ncbi.nlm.nih.gov/books/NBK470243/ [Last accessed 2025 Mar 23]
    [Google Scholar]
  31. , , , , , , et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol. 2022;28:216-29.
    [CrossRef] [PubMed] [Google Scholar]
  32. , , , , , , et al. HCC biomarkers: State of the old and outlook to future promising biomarkers and their potential in everyday clinical practice. Front Oncol. 2022;12:1016952.
    [CrossRef] [PubMed] [Google Scholar]
  33. , , , , , , et al. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. World J Gastroenterol. 2023;29:343-56.
    [CrossRef] [PubMed] [Google Scholar]
  34. , . Gene expression: An overview of methods and applications for cancer research. Vet Zootec. 2016;23:532-46.
    [Google Scholar]
  35. , , . Autoimmunity: From bench to bedside Bogota (Colombia): El Rosario University Press; .
    [Google Scholar]
  36. , . Gene expression detection assay for cancer clinical use. J Cancer. 2018;9:2249-65.
    [CrossRef] [PubMed] [Google Scholar]
  37. , , , . A review of methods to monitor the modulation of mRNA stability: A novel approach to drug discovery and therapeutic intervention. J Biomol Screen. 2010;15:609-22.
    [CrossRef] [PubMed] [Google Scholar]
  38. , , . Atlas of RNA editing events affecting protein expression in aged and Alzheimer's disease human brain tissue. Nat Commun. 2021;12:7035.
    [CrossRef] [PubMed] [Google Scholar]
  39. , , . Method for detection of specific RNAs in agarose gels by transfer to diazobenzyloxymethyl-paper and hybridization with DNA probes. Proc Natl Acad Sci U S A. 1977;74:5350-4.
    [CrossRef] [PubMed] [Google Scholar]
  40. , , , , , . Gene expression: A review on methods for the study of defense-related gene differential expression in plants. Am J Plant Sci. 2013;4:64-73.
    [CrossRef] [Google Scholar]
  41. , , , , . Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma. J Gastroenterol. 1999;34:83-7.
    [CrossRef] [PubMed] [Google Scholar]
  42. , , , , , , et al. Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma. Oncology. 2007;72:45-51.
    [CrossRef] [PubMed] [Google Scholar]
  43. , , , , , . A novel biomarker TERT mRNA is applicable for early detection of hepatoma. BMC Gastroenterol. 2010;10:46.
    [CrossRef] [PubMed] [Google Scholar]
  44. , , . Human telomerase reverse transcriptase messenger RNA (TERT mRNA) as a tumor marker for early detection of hepatocellular carcinoma. Arab J Gastroenterol. 2014;15:68-71.
    [CrossRef] [PubMed] [Google Scholar]
  45. , , , , , , et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol Int. 2017;11:317-70.
    [CrossRef] [PubMed] [Google Scholar]
  46. , , . Optimization of the annealing temperature for DNA amplification in vitro. Nucleic Acids Res. 1990;18:6409-12.
    [CrossRef] [PubMed] [Google Scholar]
  47. , , , . Interaction and effect of annealing temperature on primers used in differential display RT-PCR. Nucleic Acids Res. 1998;26:1-15.
    [CrossRef] [PubMed] [Google Scholar]
  48. , , . PLoS One. . 2012;7:e53360.
    [CrossRef] [PubMed] [Google Scholar]
  49. , , , , , . Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis. Am J Gastroenterol. 2006;101:831-8.
    [CrossRef] [PubMed] [Google Scholar]
  50. , , , , , , et al. Metabolome and transcriptome integration reveals metabolic profile of hepatocellular carcinoma. Hepatol Exp. 2022;37:2321-30.
    [CrossRef] [PubMed] [Google Scholar]
  51. , , , , . Metabolomics and lipidomics screening reveal reprogrammed signaling pathways toward cancer development in non-alcoholic steatohepatitis. Int J Mol Sci. 2023;24:210.
    [CrossRef] [PubMed] [Google Scholar]
  52. , . Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1-85.
    [Google Scholar]
  53. , , , , . Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-9.
    [CrossRef] [PubMed] [Google Scholar]
  54. , . Use of the Child-Pugh score in liver disease In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; . Available from: https://www.ncbi.nlm.nih.gov/books/NBK542308/ [Last accessed 2025 Mar 23]
    [Google Scholar]
  55. , . Cirrhosis: A questioned risk factor for hepatocellular carcinoma. Trends Cancer. 2021;7:29-36.
    [CrossRef] [PubMed] [Google Scholar]
  56. , , . Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.
    [CrossRef] [PubMed] [Google Scholar]
  57. , , , , , . Developmental gene expression differences between humans and mammalian models. Cell Rep. 2020;33:108308.
    [CrossRef] [PubMed] [Google Scholar]
  58. , , . Differential cis-regulation of human versus mouse TERT gene expression in vivo: Identification of a human-specific repressive element. Proc Natl Acad Sci U S A. 2004;101:5523-8.
    [Google Scholar]
  59. , , , , , , et al. Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Arch. 2014;465:673-7.
    [CrossRef] [PubMed] [Google Scholar]
  60. , , , , , , et al. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumor types are associated with increased TERT expression and telomerase activation. Eur J Cancer. 2015;51:969-76.
    [CrossRef] [PubMed] [Google Scholar]
  61. , , , , , , et al. Sensitive detection of hTERT mRNA in the serum of patients with hepatocellular carcinoma. Oncology. 2003;64:430-4.
    [CrossRef] [PubMed] [Google Scholar]
  62. , , , , , . Detection of telomerase activity, telomerase RNA component, and telomerase reverse transcriptase in human hepatocellular carcinoma. Hepatol Res. 2004;29:31-8.
    [CrossRef] [PubMed] [Google Scholar]
  63. , , . Serum messenger RNA as a biomarker and its clinical usefulness in malignancies. Clin Med Oncol. 2008;2:511-27.
    [CrossRef] [PubMed] [Google Scholar]
  64. , , , , . Molecular diagnosis of hepatocellular carcinoma in Egypt. Res J Appl Biotechnol. 2015;1:1-10.
    [CrossRef] [Google Scholar]
  65. , , , , , , et al. Frequency of somatic mutations in TERT promoter, TP53 and CTNNB1 genes in patients with hepatocellular carcinoma from Southern Italy. Oncol Lett. 2020;19:2368-74.
    [CrossRef] [PubMed] [Google Scholar]
  66. , , , , , , et al. Significance of TERT genetic alterations and telomere length in hepatocellular carcinoma. Cancers (Basel). 2021;13:2160.
    [CrossRef] [PubMed] [Google Scholar]
  67. , , , , , , et al. Diagnostic value of hTERT mRNA in combination with AFP, AFP-L3%, and des-γ-carboxyprothrombin for screening of hepatocellular carcinoma in liver cirrhosis patients HBV-or HCV-related. Cancer Inform. 2022;21:11769351221100730.
    [CrossRef] [PubMed] [Google Scholar]
  68. . Non-alcoholic steatohepatitis and cancer. Clin Liver Dis. 2007;11:191-207.
    [CrossRef] [PubMed] [Google Scholar]
  69. , , , , , , et al. Risk of cirrhosis and hepatocellular cancer in patients with NAFLD and normal liver enzymes. Hepatology. 2020;72:1242-52.
    [CrossRef] [PubMed] [Google Scholar]
  70. , , . Alanine aminotransferase (ALT) test In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; . Available from: https://www.ncbi.nlm.nih.gov/books/NBK559278/ [Last accessed 2025 Mar 23]
    [Google Scholar]
  71. . The clinical significance of alterations in transaminase activities of serum and other body fluids. Adv Clin Chem. 1958;1:313-51.
    [CrossRef] [Google Scholar]
  72. , , . Liver enzyme alteration: A guide for clinicians. CMAJ. 2005;172:367-79.
    [CrossRef] [PubMed] [Google Scholar]
  73. . Alanine aminotransferase: A clinical and regulatory tool for detecting liver injury-past, present, and future. Clin Pharmacol Ther. 2012;92:332-9.
    [CrossRef] [PubMed] [Google Scholar]
  74. . Alanine aminotransferase (ALT) Nihon Rinsho. 1995;53:1146-50.
    [Google Scholar]
  75. , , , , , , et al. Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores. PLoS One. 2017;12:e0179732.
    [CrossRef] [PubMed] [Google Scholar]
  76. . What is a nodule? . Verywell Health. Available from: https://www.verywellhealth.com/nodule-7106246 [Last accessed 2025 Mar 23]
    [Google Scholar]
  77. , , , . Telomeres and telomerase in the development of liver cancer. Cancers (Basel). 2020;12:2048.
    [CrossRef] [PubMed] [Google Scholar]
  78. , , , , , , et al. Phenotypic and molecular changes in nodule-in-nodule hepatocellular carcinoma with pathogenetic implications. Histopathology. 2018;73:601-11.
    [CrossRef] [PubMed] [Google Scholar]
Show Sections